IK backs biotech company Mabtech

As part of the deal, Merieux Equity Partners bought a minority stake alongside IK, while the company's founders and management team continued to be invested in the business and retained a minority holding.

The GP deployed capital from its IK Small Cap II Fund, which  closed on its €550m hard-cap in February 2018. The fund targets majority buyouts in companies with enterprise values of up to €100m across France and the DACH, Nordic and Benelux regions. It will also make selected minority buyouts. 

The GP launched a new flagship fund this year, IK IX, which has a target of €2.5bn and invests in mid-market companies with enterprise values of €100-500m, deploying equity tickets in the €50-150m range.

Company
Founded in 1986 and based in Nacka Strand, near Stockholm, Mabtech is a biotech company specialising in the production of monoclonal antibodies used in detection platform techniques like ELISpot and FluoroSpot to study immune responses to cancer, allergies and infectious diseases, as well as to monitor vaccine trials.

To complement its offering, the company also entered the instruments market by launching its first reader, Iris, in December 2018.

People
IK Investment Partners – Erik Ingemarsson (partner).
Merieux Equity Partners – Benoit Chastaing (senior partner).
Mabtech – Niklas Ahlborg (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Buyouts
• Nordics
• Healthcare
• IK Investment Partners
• Sweden